Entain Plc (LON:ENT – Get Free Report) insider Ricky Sandler sold 1,661,500 shares of Entain stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of GBX 638 ($8.48), for a total transaction of £10,600,370 ($14,090,615.45).
Entain Trading Up 2.4 %
Shares of LON ENT traded up GBX 16 ($0.21) on Tuesday, reaching GBX 687.80 ($9.14). 2,795,713 shares of the company traded hands, compared to its average volume of 7,467,757. Entain Plc has a fifty-two week low of GBX 452.50 ($6.01) and a fifty-two week high of GBX 834.20 ($11.09). The company has a 50 day moving average of GBX 617.60 and a 200 day moving average of GBX 688.37. The stock has a market capitalization of £4.42 billion, a PE ratio of -9.38, a P/E/G ratio of 0.92 and a beta of 1.19. The company has a current ratio of 0.82, a quick ratio of 0.74 and a debt-to-equity ratio of 188.61.
Wall Street Analysts Forecast Growth
ENT has been the topic of a number of recent research reports. Shore Capital restated a “buy” rating on shares of Entain in a research note on Tuesday, April 29th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,000 ($13.29) price target on shares of Entain in a research report on Thursday, May 1st.
About Entain
Entain plc (LSE: ENT) is a FTSE100 company and is one of the world’s largest sports betting and gaming groups, operating both online and in the retail sector. The Group owns a comprehensive portfolio of established brands; Sports brands include BetCity, bwin, Coral, Crystalbet, Eurobet, Ladbrokes, Neds, Sportingbet, Sports Interaction, STS, SuperSport and TAB NZ; Gaming brands include Foxy Bingo, Gala, GiocoDigitale, Ninja Casino, Optibet, Partypoker and PartyCasino.
Read More
- Five stocks we like better than Entain
- How to trade using analyst ratings
- 3 Mid-Cap Medical Stocks Outperforming the Market
- Following Congress Stock Trades
- The Top-Ranked Insider Buys From April by Market Cap
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Entain Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entain and related companies with MarketBeat.com's FREE daily email newsletter.